Patents Assigned to Guangzhou Institutes of Biomedicine and Health
-
Patent number: 9782443Abstract: The usage of a stem cell in preparation of a tooth-like structure is provided. And a culture medium, a method for preparing an epithelial-like cell, a kit for preparing an ameloblast, a method for preparing an ameloblast are also provided. Specifically, the culture medium comprises a basal medium, which is DMEM/F12 medium; N2 supplement; retinoic acid; and BMP-4.Type: GrantFiled: February 5, 2013Date of Patent: October 10, 2017Assignee: Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of SciencesInventors: Duanqing Pei, Jinglei Cai, Pengfei Liu, Shubin Chen, Yanmei Zhang
-
Publication number: 20170283398Abstract: Disclosed are a 2-aminopyrimidine compound and pharmaceutical composition and use thereof. The structure of the 2-aminopyrimidine compound is as represented by formula I, in the formula, R1, R2, R3, R4, R5, X, Y, Z, W, (i) being as defined in the specification and the claims. Such compounds effectively inhibit the growth of a variety of tumor cells and have inhibitory effects on EGFR and IGF1R protease, and can be used for preparing antineoplastic drugs and overcome the tolerance induced by the existing drugs such as gefitinib, erlotinib and the like. The compound has selectivity for tumors, in particular the wild-type non-small cell lung cancer and have good pharmacokinetic characteristics.Type: ApplicationFiled: November 18, 2015Publication date: October 5, 2017Applicants: Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCESInventors: Ke Ding, Jian Ding, Shingpan Chan, Meiyu Geng, Xiaomei Ren, Hua Xie, Zhengchao Tu, Yi Chen
-
Patent number: 9770432Abstract: The present invention discloses deuterated benzopyran compounds having structure features as shown in Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or prodrug molecules thereof. With excellent anti-inflammatory and analgesic effects and the capability to inhibit growth of tumor cells, such compounds are novel COX-2 selective inhibitors. The compounds and pharmaceutically acceptable salts thereof disclosed by the present application can be applied in preparing anti-inflammatory and analgesic drugs and drugs for treating or preventing tumors.Type: GrantFiled: June 14, 2016Date of Patent: September 26, 2017Assignee: Guangzhou Institutes of Biomedicine And Health, Chinese Academy of SciencesInventors: Yanmei Zhang, John Jeffrey Talley, Mark G. Obukowicz, Zhengchao Tu, Micky Tortorella, Yican Wang, Jianqi Liu, Yan Chen, Xiaorong Liu, Xin Lu
-
Patent number: 9763914Abstract: The present invention discloses deuterated benzopyran compounds having structure features as shown in Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or prodrug molecules thereof. With excellent anti-inflammatory and analgesic effects and the capability to inhibit growth of tumor cells, such compounds are novel COX-2 selective inhibitors. The compounds and pharmaceutically acceptable salts thereof disclosed by the present application can be applied in preparing anti-inflammatory and analgesic drugs and drugs for treating or preventing tumors.Type: GrantFiled: June 14, 2016Date of Patent: September 19, 2017Assignee: Guangzhou Institutes of Biomedicine And Health, Chinese Academy of SciencesInventors: Yanmei Zhang, John Jeffrey Talley, Mark G. Obukowicz, Zhengchao Tu, Micky Tortorella, Yican Wang, Jianqi Liu, Yan Chen, Xiaorong Liu, Xin Lu
-
Publication number: 20170159017Abstract: The present disclosure provides a method for producing a cell with exogenous mitochondria by obtaining synthetic mitochondria via introduction of exogenous mitochondrial DNA into mitochondria or empty mitochondrial shells, and incorporating the same into mammalian cells via endocytosis. As such, effective functionality of exogenous mitochondria in cells is realized. The synthetic mitochondrial DNA genes introduced according to the present disclosure can be stably expressed and effectively passaged. The method for introducing exogenous mitochondrial DNA into mammalian cells as disclosed herein may be used as a whole new mitochondrial molecular cloning means to perform site-directed mutagenesis, gene insertion, gene knockout, gene rearrangement, and the like in mitochondria. Therefore, any molecular cloning modification can be performed on a mammalian mitochondrial DNA, which is of great importance to therapeutic schemes of diseases derived from mitochondrial DNA mutations.Type: ApplicationFiled: August 25, 2014Publication date: June 8, 2017Applicant: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of SciencesInventors: Xingguo Liu, Duanqing Pei, Jinglei Liu, Deyang Yao, Xuebin Liu
-
Publication number: 20170037376Abstract: Provided are a method for preparing an induced pluripotent stem cell and a composition used in the method. The method comprises: introducing a composition for promoting the formation of an induced pluripotent stem cell into a somatic cell, the composition comprising: (i) a c-Jun antagonist and one group of factors from among the following seven such groups: (1) Sox2, Klf4 and c-Myc, (2) Klf4 and c-Myc, (3) Oct3/4, Klf4 and c-Myc, (4) Sox2, Nanog and Lin28, (5) Oct3/4, Nanog and Lin28, (6) Oct3/4, Klf and Sox2, and (7) Klf4 and Sox2; or (ii) the c-Jun antagonist, Jhdm1b and Id1, and at least one of Glis1, Sall4 or Lrh1; or (iii) the c-Jun antagonist, Jhdm1b and Id1, and at least one of: Oct4, Klf4, Sox2, Lin28, Esrrb, Lef1, Utf1 or miRNA C. The present method allows for successful preparation of induced pluripotent stem cells with no generation of abnormal chromosomes.Type: ApplicationFiled: November 12, 2014Publication date: February 9, 2017Applicant: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCESInventors: Duanqing PEI, Jing LIU, Jiekai CHEN, Meixiu PENG
-
Patent number: 9452220Abstract: The present invention discloses coupling compounds of a structure as shown in Formula I, II or III formed by connecting NSAID anti-inflammatory and analgesic drugs and EGFR inhibitors by ester bonds or pharmaceutically acceptable salts or stereoisomers thereof or prodrug molecules thereof: where R is a NSAID anti-inflammatory and analgesic drug. In the present invention, the coupling compounds obtained by coupling NSAID anti-inflammatory and analgesic drugs with EGFR inhibitors have excellent therapeutic effects of tumors and provide new drugs for clinic treatment options.Type: GrantFiled: December 23, 2014Date of Patent: September 27, 2016Assignee: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCESInventors: Yanmei Zhang, Ke Ding, Jinxi Liao, Yican Wang, Panyu Chen
-
Publication number: 20160175453Abstract: The present invention discloses coupling compounds of a structure as shown in Formula I, II or III formed by connecting NSAID anti-inflammatory and analgesic drugs and EGFR inhibitors by ester bonds or pharmaceutically acceptable salts or stereoisomers thereof or prodrug molecules thereof: where R is a NSAID anti-inflammatory and analgesic drug. In the present invention, the coupling compounds obtained by coupling NSAID anti-inflammatory and analgesic drugs with EGFR inhibitors have excellent therapeutic effects of tumors and provide new drugs for clinic treatment options.Type: ApplicationFiled: December 23, 2014Publication date: June 23, 2016Applicant: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of SciencesInventors: Yanmei Zhang, Ke Ding, Jinxi Liao, Yican Wang, Panyu Chen
-
Patent number: 9371305Abstract: The present invention discloses deuterated benzopyran compounds having structure features as shown in Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or prodrug molecules thereof. With excellent anti-inflammatory and analgesic effects and the capability to inhibit growth of tumor cells, such compounds are novel COX-2 selective inhibitors. The compounds and pharmaceutically acceptable salts thereof disclosed by the present application can be applied in preparing anti-inflammatory and analgesic drugs and drugs for treating or preventing tumors.Type: GrantFiled: August 10, 2012Date of Patent: June 21, 2016Assignee: Guangzhou Institutes of Biomedicine And Health, Chinese Academy of SciencesInventors: Yanmei Zhang, John Jeffrey Talley, Mark G. Obukowicz, Zhengchao Tu, Micky Tortorella, Yican Wang, Jianqi Liu, Yan Chen, Xiaorong Liu, Xin Lu
-
Patent number: 9353089Abstract: The present invention provides aminohydantoin anti-malarial agents. In some embodiments, these agents have the property of functions of targeting malarial aspartic proteases while at the same time having low activity against human BACE. Methods of employing such agents are also provided.Type: GrantFiled: March 26, 2014Date of Patent: May 31, 2016Assignees: Saint Louis University, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of SciencesInventors: Xiaoping Chen, Ke Ding, Marvin J. Meyers, Micky D. Tortorella, Jing Xu
-
Patent number: 9238643Abstract: A compound represented by formula (I) and the pharmaceutical acceptable salt thereof are disclosed, wherein, R1, R2, R3, R4, R5 and Ar are defined as those in the specification.Type: GrantFiled: September 6, 2010Date of Patent: January 19, 2016Assignee: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of SciencesInventors: Wenhui Hu, Guifa Zhong, Ling Yang, Hongjiang Xu
-
Patent number: 9163218Abstract: The present invention relates to a method for increasing the efficiency of inducing pluripotent stem cells by utilizing genes Jhdm1a that modify histone. By utilizing Jhdm1a, and a stem cell inducing factor, the present invention increases the efficiency of inducing pluripotent stem cells and increases the quality of induced pluripotent stem cells. The stem cell inducing factor is a combination of Oct4 and Klf4, or a combination of Sox2, Oct4, and Klf4, or a combination of Oct4 and Sox2, and Oct4 alone. The method further comprises exposing the cells to vitamin C, which further increases the efficiency of inducing pluripotent stem cells as compared with the case where no vitamin C is used. By using less stem cell reducing factors, the method of the present invention reduces the potential carcinogenicity, obtains a high inducing efficiency, and provides high-quality induced pluripotent stem cells capable of germ-line transmission.Type: GrantFiled: August 27, 2013Date of Patent: October 20, 2015Assignee: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH CHINESE ACADEMY OF SCIENCESInventors: Duanqing Pei, Tao Wang
-
Publication number: 20150133538Abstract: The present invention discloses deuterated benzopyran compounds having structure features as shown in Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or prodrug molecules thereof. With excellent anti-inflammatory and analgesic effects and the capability to inhibit growth of tumor cells, such compounds are novel COX-2 selective inhibitors. The compounds and pharmaceutically acceptable salts thereof disclosed by the present application can be applied in preparing anti-inflammatory and analgesic drugs and drugs for treating or preventing tumors.Type: ApplicationFiled: August 10, 2012Publication date: May 14, 2015Applicant: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of SciencesInventors: Yanmei Zhang, John Jeffrey Talley, Mark G. Obukowicz, Zhengchao Tu, Micky Tortorella, Yican Wang, Jianqi Liu, Yan Chen, Xiaorong Liu, Xin Lu
-
Publication number: 20150030570Abstract: Provided are a culture medium for preparing neural stem cell and use thereof, the culture medium for preparing neural stem cell comprising: a basic culture medium suitable for the growth of stem cell, and a cell signal pathway inhibitor selected from at least one of GSK inhibitor, MEK inhibitor, TGF-? inhibitor, ROCK inhibitor and BMP inhibitor.Type: ApplicationFiled: February 6, 2013Publication date: January 29, 2015Applicant: Guangzhou Institutes of Biomedicine and Health Chinese Academy of SciencesInventors: Guangjin Pan, Duanqing Pei, Lihui Wang, Linli Wang, Yanting Xue
-
Patent number: 8853221Abstract: The compounds according to formula (VIII), their pharmaceutically acceptable acid or base addition salts, and the uses thereof. These compounds and their pharmaceutically acceptable acid or base addition salts can be used for preparing medicaments for modulating estrogen related receptors (ERR), and treating metabolic diseases, such as high blood fat, fatty liver, hyperglycemia, diabetes, obesity. The substituents of the formula are defined in the description.Type: GrantFiled: March 6, 2009Date of Patent: October 7, 2014Assignee: Guangzhou Institute of Biomedicine & Health, Chinese Academy of SciencesInventors: Ke Ding, Chiwai Wong, Lijie Peng, Zhanfang Kang, Xi Zhou
-
Publication number: 20140296532Abstract: The present invention provides aminohydantoin anti-malarial agents. In some embodiments, these agents have the property of functions of targeting malarial aspartic proteases while at the same time having low activity against human BACE. Methods of employing such agents are also provided.Type: ApplicationFiled: March 26, 2014Publication date: October 2, 2014Applicants: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Saint Louis UniversityInventors: Xiaoping Chen, Ke Ding, Marvin J. Meyers, Micy D. Tortorella, Jing Xu
-
Publication number: 20140296216Abstract: A compound of formula (I) or (II) and use of the compound in the preparation of drugs for treating cancer are disclosed. The study shows that the compounds can inhibit the growth of many kinds of tumor cells, can be used for targeting epidermal growth factor receptor (EGFR), and particularly can inhibit tumor cells with single or multiple mutations of EGFR (T790M). Therefore, the compound can be used as EGFR inhibitor to treat cancer and has a relatively large application value.Type: ApplicationFiled: December 21, 2011Publication date: October 2, 2014Applicant: GUANGZHOU INSTITUTE OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCESInventors: Ke Ding, Shaohua Chang, Shilin Xu, Lianwen Zhang, Zhengchao Tu, Jian Ding, Meiyu Geng, Yi Chen
-
Patent number: 8846671Abstract: The heterocyclic alkynyl benzene compounds of formula (I), their pharmaceutically acceptable salts and stereoisomers thereof, as well as application in preparing drugs for preventing or treating tumors. The compounds can overcome the clinically induced resistance against Gleevec.Type: GrantFiled: June 3, 2011Date of Patent: September 30, 2014Assignee: Guangzhou Institute of Biomedicine and Health, Chinese Academy of SciencesInventors: Ke Ding, Deping Wang, Duanqing Pei, Zhang Zhang, Mengjie Shen, Kun Luo, Yubing Feng
-
Publication number: 20140193912Abstract: The present invention relates to a method for increasing the efficiency of inducing pluripotent stem cells by utilizing genes Jhdm1a that modify histone. By utilizing Jhdm1a, and a stem cell inducing factor, the present invention increases the efficiency of inducing pluripotent stem cells and increases the quality of induced pluripotent stem cells. The stem cell inducing factor is a combination of Oct4 and Klf4, or a combination of Sox2, Oct4, and Klf4, or a combination of Oct4 and Sox2, and Oct4 alone. The method further comprises exposing the cells to vitamin C, which further increases the efficiency of inducing pluripotent stem cells as compared with the case where no vitamin C is used. By using less stem cell reducing factors, the method of the present invention reduces the potential carcinogenicity, obtains a high inducing efficiency, and provides high-quality induced pluripotent stem cells capable of germ-line transmission.Type: ApplicationFiled: August 27, 2013Publication date: July 10, 2014Applicant: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCESInventors: Duanqing PEI, Tao WANG
-
Publication number: 20130323782Abstract: Methods for generating iPSCs and differentiated cells of interest by reprogramming donor cells that have been obtained in a non-invasive manner. In particular, the donor cells are exfoliated epithelial urine cells. The differentiated cells can be obtained by differentiation of the reprogrammed iPSCs or by direct reprogramming the urine cells.Type: ApplicationFiled: December 23, 2011Publication date: December 5, 2013Applicants: Guangzhou Institute of Biomedicine and Health, Universitat fur Bodenkultur WienInventors: Miguel Esteban, Johannes Grillari, Regina Grillari, Duanqing Pei, Ting Zhou